InvestSMART

BCAL Diagnostics Limited (ASX: BDX) - Announcements

- Current share price for BDX : $0.060

ASX company news and announcements for BCAL Diagnostics Limited (BDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All BCAL Diagnostics Limited (BDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than BCAL Diagnostics Limited (BDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for BCAL Diagnostics Limited (BDX)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$22 Notification regarding unquoted securities - BDX 18 Nov 2026 11:57AM $0.060 $0.060 fallen by 0%
$22 Change of Director's Interest Notice 18 Nov 2026 11:54AM $0.060 $0.060 fallen by 0%
$22 BCAL Expands Breast Cancer Biomarker Program 17 Nov 2026 8:43AM $0.060 $0.060 fallen by 0%
$22 Notification of cessation of securities - BDX 13 Nov 2026 5:44PM $0.060 $0.060 fallen by 0%
$22 Notification of cessation of securities - BDX 13 Nov 2026 5:44PM $0.060 $0.060 fallen by 0%
$22 Application for quotation of securities - BDX 13 Nov 2026 5:38PM $0.060 $0.060 fallen by 0%
$22 TOV: GSS - Panel Receives Application 13 Nov 2026 5:29PM $0.060 $0.060 fallen by 0%
$22 Change of Director's Interest Notice 11 Nov 2026 3:45PM $0.064 $0.060 fallen by 6.25%
$22 Quarterly Activities/Appendix 4C Cash Flow Report 30 Oct 2026 11:40AM $0.080 $0.060 fallen by 25%
$22 BCAL Welcomes Dr John Melki's Appointment to GSS Board 28 Oct 2026 4:07PM $0.080 $0.060 fallen by 25%
$22 Results of Meeting 19 Oct 2026 2:14PM $0.079 $0.060 fallen by 24.05%
$22 AGM 2026 Presentation 19 Oct 2026 10:43AM $0.079 $0.060 fallen by 24.05%
$22 BREASTESTplus Research Presented at Lipidomic Conference 19 Oct 2026 9:27AM $0.079 $0.060 fallen by 24.05%
$22 GSS: Response to Media Speculation & BCAL letter to GSS 16 Oct 2026 8:25PM $0.079 $0.060 fallen by 24.05%
$22 Letter to Genetic Signatures Ltd Shareholders 15 Oct 2026 2:13PM $0.079 $0.060 fallen by 24.05%
$22 Investor Presentation - Transforming Cancer Detection 6 Oct 2026 10:15AM $0.090 $0.060 fallen by 33.33%
$22 Change in substantial holding 1 Oct 2026 6:23PM $0.090 $0.060 fallen by 33.33%
$22 BREASTESTplus 2 clinically validated 30 Sep 2026 8:48AM $0.081 $0.060 fallen by 25.93%
$22 BCAL Introduces Avantect Multi-Cancer Early Detection Test 23 Sep 2026 10:43AM $0.082 $0.060 fallen by 26.83%
$22 Letter to Shareholders re Annual General Meeting 18 Sep 2026 8:22AM $0.086 $0.060 fallen by 30.23%
$22 Notice of Annual General Meeting/Proxy Form 18 Sep 2026 8:22AM $0.086 $0.060 fallen by 30.23%
$22 Clarification of BCAL's Position in Relation to GSS 10 Sep 2026 1:19PM $0.065 $0.060 fallen by 7.69%
$22 BCAL Seeks Board Change at Genetic Signatures 3 Sep 2026 12:40PM $0.069 $0.060 fallen by 13.04%
$22 Investor Presentation September 2026 3 Sep 2026 11:47AM $0.069 $0.060 fallen by 13.04%
$22 Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM 31 Aug 2026 2:30PM $0.066 $0.060 fallen by 9.09%

1 - 25 of 292 results

Page 1 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.